Dermatology

Psoriasis is a debilitating inflammation of skin affecting approximately 7.4 million adults in the United States. Recent researches demonstrating a surge in the Psoriasis prevalence indicating moderate-to-severe psoriasis, absence of safe, effective and easy to administer therapies has clearly resulted in several major pharmaceuticals to invest in Psoriasis treatment. Studies have revealed that Psoriasis also carries an increased risk for cardiovascular disease, psoriatic arthritis, obesity, and depression, in addition to already compromised quality of life. All of these complications in Psoriasis treatment calls for pharma innovation in this domain that can offer an ...